
The study compared the effects of torsemide and furosemide on patient-reported outcomes in heart failure (HF) patients. This study included 2,859 hospitalized HF patients randomized to receive either torsemide or furosemide. The secondary endpoints examined were the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and the Patient Health Questionnaire-2 (PHQ-2) over 12 months. The results showed no significant difference between torsemide and furosemide regarding improvements in KCCQ-CSS or the proportion of patients with PHQ-2 scores indicating depression. These findings were consistent across various subgroups and baseline health status. The study suggests that torsemide did not provide superior symptom relief or quality of life compared to furosemide in HF patients.
Like
Save
Share